Both in Pharmaceuticals
Ultragenyx Pharmaceutical vs Pacira BioSciences
Over the past year RARE returned −53.0% and PCRX returned +60.1%; their daily moves had a correlation of 0.10.
RARE −53.0% PCRX +60.1%Growth of $1, one year, split-adjusted
| Metric | RARE | PCRX |
|---|---|---|
| Price | $14.90 | $36.40 |
| Market cap | $1.47B | $1.45B |
| Today | −0.13% | +0.25% |
| 1 month | +14.0% | +51.2% |
| 6 months | −40.8% | +55.4% |
| Year to date | −35.2% | +40.6% |
| 1 year | −53.5% | +63.5% |
| Revenue growth (YoY) | +28.1% | +6.2% |
| Gross margin | 84.1% | 77.0% |
| Net margin | −43.0% | 2.4% |
| P/E (TTM) | — | 99.2× |
| Price / sales | 2.0× | 1.9× |
| Net cash | $292.0M | -$112.1M |
| Dividend yield | — | — |
| Volatility (60d) | 127.6% | 82.8% |
| Short % of float | 21.8% | 21.2% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).